Printer Friendly

PHARMACEUTICAL PRODUCTS DEVELOPED IN ISRAEL BY TEVA PHARMACEUTICAL INDUSTRIES CHOSEN FOR PRESTIGIOUS CORPORATE HONOR IN U.S.

PHARMACEUTICAL PRODUCTS DEVELOPED IN ISRAEL BY TEVA PHARMACEUTICAL
 INDUSTRIES CHOSEN FOR PRESTIGIOUS CORPORATE HONOR IN U.S.
 Lemmon Company, the Pennsylvania drug manufacturer fully owned by Israel-based Teva Pharmaceutical Industries Ltd., has been chosen by the National Organization for Rare Disorders (NORD) as a Corporate Honoree for development of three important drugs, two of which were developed and produced by Teva.
 Lemmon Company is one of the 10 largest producers of generic drugs in the United States; approximately one-third of its total sales in that country are of generic drugs manufactured at Teva's FDA approved plants in Israel.
 The award will be presented at NORD's Annual Tribute Banquet, at the Stouffer Concourse Hotel (2399 Jefferson Davis Highway, Arlington, Va.), at 8 p.m., on Monday, May 18.
 At its Annual Tribute Banquet, NORD honors organizations and individuals for their contribution to those who suffer from rare disorders.
 Two of the three drugs for which Lemmon will be honored, were developed jointly by Teva's Research and Development Division and by scientists from Israel's Chaim Weizmann Institute of Science.
 The first of these, called Osteo D3, is intended as a treatment for a bone disease which often occurs in patients with advanced renal failure. The drug is marketed in Israel as well as in a number of other countries. Osteo D3 is also in the process of registration in several countries and is undergoing a multi-center Phase II clinical trial in the United States, expected to be completed in January 1993.
 The second drug is COP-1, intended as a treatment for Multiple Sclerosis. The drug is currently undergoing advanced clinical trials in the United States, which have produced encouraging results thus far. Registration is expected in early 1995.
 Leli Horowitz, the president of Teva Pharmaceutical Industries Ltd., will be in town for the ocassion and will be available for interviews. For interview requests, call Ruth Yaron, press counsellor, Israeli Embassy, 202-364-5538. For additional information on the event, call the contact below.
 CONTACT: Abbey F. Meyers of the National Organization for Rare Disorders, 703-418-6800.
 -0- 5/15/92


CO: Teva Pharmaceutical Industries Ltd.; National Organization for
 Rare Disorders ST: Pennsylvania, Virginia, District of Columbia IN: MTC SU:


DS -- DC024 -- 0863 05/15/92 15:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 1992
Words:373
Previous Article:WASHINGTON STATE DEPARTMENT OF AGRICULTURE SAYS ASIAN GYPSY MOTH SPRAY OPERATIONS AHEAD OF SCHEDULE
Next Article:HONEYWELL TO REDEEM 9-3/8 PERCENT SINKING FUND DEBENTURES
Topics:


Related Articles
TEVA PHARMACEUTICALS TO MARKET COLUMBIA LABORATORIES' WOMEN'S HEALTH CARE PRODUCTS IN ISRAEL
FDA Grants Marketing Clearance for COPAXONE (Glatiramer Acetate for Injection) for Reducing Relapses
AAI Signs Drug Development Agreement With Teva
TEVA GETS FIRST FDA APPROVAL OF KETOCONAZOLE 2% CREAM.
Computer Associates Unicenter TNG Provides Automated Support Remedy For Teva Pharmaceutical Industries.
TEVA SIGNS PACT TO BUY HONEYWELL PHARMACEUTICAL IN ITALY.
FDA GRANTS "APPROVABLE" STATUS FOR TEVA'S ANDA FOR GABAPENTIN.
Yet Another Study Shows COPAXONE(R) Did Not Generate Neutralizing Antibodies; COPAXONE(R) Did Not Develop Neutralizing Antibodies That Have Been...
FDA GRANTS TENTATIVE APPROVAL OF SICOR'S FLUMAZENIL INJECTION.
Ranbaxy Announces the Launch of Quinapril Tablets by Teva, Based on an Agreement Between Ranbaxy and Teva.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters